Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 06/10–06/11 | 06/11 | 572 sh2 trades | $247.65avg. | $141,655.8 | −1.0% | |
Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 06/09–06/10 | 06/10 | 600 sh2 trades | $241.70avg. | $145,017 | −42.0% | |
Mark ColemanDirector | Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 06/10 | 06/10 | 643 sh | $249.00 | $160,107 | −2.1% |
Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 06/09 | 06/09 | 49,670 sh | $241.01 | $11,970,966.7 | −87.3% | |
Pizzie NickCFO | Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 06/09 | 06/09 | 33,000 sh | $240.09 | $7,922,970 | −43.5% |
Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 05/29–06/02 | 06/02 | 17,537 sh3 trades | $229.20avg. | $4,019,470.43 | −37.2% | |
Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 05/04–05/05 | 05/05 | 4,750 sh2 trades | $227.95avg. | $1,082,770.92 | −100.0% | |
Ari MaizelChief Commercial Officer | Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 04/22 | 04/23 | 7,500 sh | $182.42 | $1,368,150 | −100.0% |
Mark ColemanDirector | Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 02/26 | 02/27 | 25,000 sh | $161.11 | $4,027,750 | −34.7% |
Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 02/26 | 02/27 | 35,378 sh | $161.88 | $5,726,990.64 | −100.0% | |
Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 02/02 | 02/02 | 32,410 sh | $185.60 | $6,015,296 | −81.8% | |
Pizzie NickCFO | Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 01/22 | 01/23 | 12,000 sh | $187.92 | $2,255,040 | −22.0% |
Ari MaizelChief Commercial Officer | Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 01/21 | 01/23 | 7,500 sh | $184.44 | $1,383,300 | −100.0% |
Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 01/05–01/07 | 01/07 | 139,414 sh3 trades | $171.30avg. | $23,881,617.52 | −95.1% | |
Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 25/12/31 | 01/02 | 37,577 sh2 trades | $165.18avg. | $6,206,968.86 | −79.0% | |
Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 25/12/02–25/12/04 | 25/12/04 | 79,973 sh3 trades | $145.66avg. | $11,648,582.34 | −91.7% | |
Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 25/11/03–25/11/05 | 25/11/05 | 163,939 sh3 trades | $133.07avg. | $21,815,669.06 | −95.8% | |
Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 25/10/06–25/10/08 | 25/10/08 | 45,384 sh3 trades | $119.38avg. | $5,418,059.86 | −86.3% | |
Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 25/09/22 | 25/09/22 | 10,000 sh | $115.96 | $1,159,600 | −100.0% | |
Axsome TherapeuticsAXSM | Open-market sale10b5-1 plan | 25/09/16 | 25/09/17 | 45,783 sh2 trades | $114.48avg. | $5,241,126.77 | −100.0% |